Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX TWISTHALER versus HYDELTRASOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX TWISTHALER versus HYDELTRASOL.
ASMANEX TWISTHALER vs HYDELTRASOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators (e.g., cytokines, chemokines, adhesion molecules) and suppression of inflammatory cell migration and activation in the airways.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
Inhalation: 1-2 inhalations twice daily (morning and evening). Typical adult dose: 200-400 mcg twice daily. Maximum: 800 mcg/day.
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation via ASMANEX TWISTHALER is approximately 5 hours (range 4–6 hours) in patients with asthma. This relatively short half-life supports twice-daily or once-daily dosing with sustained clinical effect due to prolonged local retention in the lungs.
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver via CYP3A4. Unchanged drug and metabolites are excreted primarily in the feces via biliary elimination (approximately 74% of a single oral dose) and to a minor extent in the urine (approximately 8%). For inhaled doses, renal excretion of unchanged drug is negligible (<1% of administered dose).
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid